Actinium-225 (Ac-225) is a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/24/2024 | $75.00 → $90.00 | Equal Weight → Underweight | Barclays |
| 6/27/2024 | $113.00 | Buy | Janney |
| 6/26/2024 | $110.00 | Buy | BTIG Research |
| 6/3/2024 | Buy | CLSA | |
| 3/25/2024 | $110.00 → $95.00 | Buy → Hold | Truist |
| 11/3/2023 | $79.00 → $82.00 | Overweight → Neutral | Alembic Global Advisors |
| 9/28/2023 | $86.00 | Buy | Deutsche Bank |
| 8/4/2023 | $61.00 → $85.00 | Neutral → Outperform | Robert W. Baird |
3Q24 revenues of $672.0 million 3Q24 net income of $69.6 million, adjusted EBITDA(1) of $127.0 million 3Q24 diluted GAAP EPS of $0.76, non-GAAP(1) EPS of $0.83 Expanding special materials portfolio with announced acquisition of A.O.T., a sole source provider of depleted uranium and finished specialty metals for mission critical defense applications; targeting close by year-end 2024 non-GAAP EPS(1) guidance raised to ~$3.20 Preliminary 2025 guidance for revenue, non-GAAP EPS(1) and adjusted EBITDA(1) to grow mid-to-high-single-digits; free cash flow(1) growth to be sustained at 10% or higher BWX Technologies, Inc. (NYSE:BWXT) ("BWXT", "we", "us" or the "Company") reported third
BWX Technologies, Inc. (NYSE:BWXT) and L3Harris Technologies, Inc. (NYSE:LHX) today announced the signing of a purchase agreement for BWXT to acquire L3Harris' Aerojet Ordnance Tennessee, Inc. (A.O.T.) business for approximately $100 million. A.O.T. is a leading provider of advanced specialty materials, fabrication and high-strength alloy manufacturing, including depleted uranium engineered materials. A.O.T. will further enhance BWXT's capabilities to develop and manufacture advanced materials and products for commercial, military and space applications. "With decades of experience in specialized materials and metallurgy, A.O.T. brings exciting resources and expertise to BWXT," said Rex G
BWX Technologies, Inc. (NYSE:BWXT) and L3Harris Technologies, Inc. (NYSE:LHX) today announced the signing of a purchase agreement for BWXT to acquire L3Harris' Aerojet Ordnance Tennessee, Inc. (A.O.T.) business for approximately $100 million. A.O.T. is a leading provider of advanced specialty materials, fabrication and high-strength alloy manufacturing, including depleted uranium engineered products. A.O.T. will further enhance BWXT's capabilities to develop and manufacture advanced materials and products for commercial, military and space applications. "With decades of experience in specialized materials and metallurgy, A.O.T. brings exciting resources and expertise to BWXT," said Rex Ge
10-Q - BWX Technologies, Inc. (0001486957) (Filer)
8-K - BWX Technologies, Inc. (0001486957) (Filer)
10-Q - BWX Technologies, Inc. (0001486957) (Filer)
SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)
SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)
SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)
4 - BWX Technologies, Inc. (0001486957) (Issuer)
4 - BWX Technologies, Inc. (0001486957) (Issuer)
4 - BWX Technologies, Inc. (0001486957) (Issuer)
Barclays downgraded BWX Technologies from Equal Weight to Underweight and set a new price target of $90.00 from $75.00 previously
Janney initiated coverage of BWX Technologies with a rating of Buy and set a new price target of $113.00
BTIG Research initiated coverage of BWX Technologies with a rating of Buy and set a new price target of $110.00
Barclays analyst David Strauss downgrades BWX Technologies (NYSE:BWXT) from Equal-Weight to Underweight and raises the price target from $75 to $90.
Actinium-225 (Ac-225) is a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE:BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues. Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. Pursuant to the multi-year MSA, the companies will work together to process and purify radium-226. The scope of the agreement also includes potential target design projects and exploration
John D. Haynes School of Welding Technology Fills Critical Training Need to Support National Defense Priorities BWX Technologies, Inc. (NYSE:BWXT) today announced the opening of the John D. Haynes School of Welding Technology at Mount Vernon High School in Mount Vernon, Indiana. The company, along with the U.S. Navy and the BlueForge Alliance, have invested $500,000 into the new school to help further the educational journeys of students interested in pursuing a career in welding. The welding school provides a direct employment opportunity for students from Mount Vernon High School to BWXT's Nuclear Operations Group in Mount Vernon. Participants can complete their high school degree and p
BWX Technologies, Inc. (NYSE:BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business' mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide. Puppo brings a wealth of experience to BWXT Medical, with over 30 years of experience in the areas of imaging, nuclear medicine, radiation therapy and biotech, in both Europe and North America. In his most recent roles, he served as chief operating officer of Radiopharm Theranostics and held various positions with Bracco. These include chief marketing and strategy officer of Bracco Imaging, pres
SMR Supplier Group Will Support Global Deployment of BWRX-300 Design BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. (NYSE:BWXT), has been selected as the first qualified supply chain company to join the GE Vernova nuclear business' supplier group that will advance the global deployment of the BWRX-300 small modular reactor (SMR). The purpose of the supplier group is to ensure a reliable, cost effective and innovative process for the manufacture and commercialization of the BWRX-300 currently under design by GE Vernova's nuclear business, GE Hitachi Nuclear Energy (GEH). Suppliers who meet pre-defined criteria, customer requirements and demonstrate a willingness to internally i
3Q24 revenues of $672.0 million 3Q24 net income of $69.6 million, adjusted EBITDA(1) of $127.0 million 3Q24 diluted GAAP EPS of $0.76, non-GAAP(1) EPS of $0.83 Expanding special materials portfolio with announced acquisition of A.O.T., a sole source provider of depleted uranium and finished specialty metals for mission critical defense applications; targeting close by year-end 2024 non-GAAP EPS(1) guidance raised to ~$3.20 Preliminary 2025 guidance for revenue, non-GAAP EPS(1) and adjusted EBITDA(1) to grow mid-to-high-single-digits; free cash flow(1) growth to be sustained at 10% or higher BWX Technologies, Inc. (NYSE:BWXT) ("BWXT", "we", "us" or the "Company") reported third
BWX Technologies, Inc. (NYSE:BWXT) will issue a press release detailing third quarter 2024 results on Monday, November 4, 2024, after market close and will host a conference call at 5:00 p.m. EST. Listen-only participants are encouraged to participate and view the supporting presentation via the Internet at www.bwxt.com/investors. The dial-in numbers for participants are (U.S.) 1-888-596-4144 and (International) 1-646-968-2525; conference ID: 4276735. A replay of the call will remain available on the BWXT website for a limited time. About BWXT At BWX Technologies, Inc. (NYSE:BWXT), we are People Strong, Innovation Driven. Headquartered in Lynchburg, Virginia, BWXT is a Defense News Top 1
2Q24 revenues of $681.5 million 2Q24 net income of $73.0 million, adjusted EBITDA(1) of $126.2 million 2Q24 diluted GAAP EPS of $0.79, non-GAAP(1) EPS of $0.82 BWXT-led JV awarded management and operations contract for the NNSA's Pantex Plant 2024 non-GAAP EPS(1) guidance revised to $3.10-$3.20 BWX Technologies, Inc. (NYSE:BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. "Second quarter results were ahead of our expectations driven by strong organic growth and crisp execution across our business lines," said Rex. D Geveden. "Our solid year-to-date performance provides us th